^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CXCL6 (C-X-C Motif Chemokine Ligand 6)

    i
    Other names: CXCL6, C-X-C Motif Chemokine Ligand 6, GCP-2, CKA-3, Granulocyte Chemotactic Protein 2, SCYB6, Small Inducible Cytokine Subfamily B (Cys-X-Cys), Member 6 (Granulocyte Chemotactic Protein 2), Chemokine (C-X-C Motif) Ligand 6 (Granulocyte Chemotactic Protein 2), Small-Inducible Cytokine B6, C-X-C Motif Chemokine 6, Chemokine Alpha 3, GCP2, Small Inducible Cytokine Subfamily B (Cys-X-Cys), Member B, Chemokine (C-X-C Motif) Ligand 6
    10d
    Cx1Mab-1: A Novel Anti-mouse CXCR1 Monoclonal Antibody for Flow Cytometry. (PubMed, Monoclon Antib Immunodiagn Immunother)
    Furthermore, Cx1Mab-1 could detect mCXCR1 by Western blot analysis. These results indicated that Cx1Mab-1 is useful for detecting mCXCR1, and provides a possibility for targeting mCXCR1-expressing cells in vivo experiments.
    Preclinical • Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • CXCR1 (Chemokine (C-X-C motif) receptor 1)
    2ms
    Acid-sensing receptor GPR4 plays a crucial role in lymphatic cancer metastasis. (PubMed, Cancer Sci)
    These results suggest that an acidic microenvironment modifies the function of lymphatic endothelial cells via GPR4, thereby promoting lymphatic cancer metastasis. Acid-sensing receptors and their downstream molecules might serve as preventive or therapeutic targets in cancer.
    Journal
    |
    CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • VCAM1 (Vascular Cell Adhesion Molecule 1)
    2ms
    Identification of a novel glioblastoma multiforme molecular subtype with poor prognosis and high immune infiltration based on oxidative stress-related genes. (PubMed, Medicine (Baltimore))
    Our study identified 10 hub genes as potential therapeutic targets in GBM subtype 2 patients, who have poorer overall survival and higher immune infiltration levels. These findings could pave the way for new treatments for this aggressive form of brain cancer.
    Journal
    |
    CSF2 (Colony stimulating factor 2) • CCR8 (C-C Motif Chemokine Receptor 8) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • MMP8 (Matrix Metallopeptidase 8) • TNFSF11 (TNF Superfamily Member 11)
    3ms
    Systematic assessment of chemokine ligand bias at the human chemokine receptor CXCR2 indicates G protein bias over β-arrestin recruitment and receptor internalization. (PubMed, Cell Commun Signal)
    This study presents an in-depth analysis of signaling bias upon CXCR2 stimulation by its chemokine ligands. Using CXCL8 as a reference ligand for bias index calculations, no ligand bias was observed between chemokines with respect to activation of separate G proteins subtypes or recruitment of β-arrestin1/2 subtypes, respectively. However, compared to β-arrestin recruitment and receptor internalization, CXCL1-3 and CXCL5-7 were biased towards G protein activation when CXCL8 was used as reference ligand.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    3ms
    Tissue contexture determines the pattern and density of tumor-infiltrating immune cells in HPV-associated squamous cell carcinomas of oropharynx and uterine cervix. (PubMed, Transl Oncol)
    Taken together, despite their having the same etiologic agent, the immune infiltration pattern significantly differs between OPSCC and CESC, with a noticeable shift toward prominent MDSC infiltration in the latter. Our data thus present a rationale for a diverse approach to targeted therapy in patients with HPV-associated tumors of different tissue origins.
    Journal • Immune cell
    |
    CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    5ms
    Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRβ/NF-κB signaling pathway. (PubMed, BMC Cancer)
    In summary, atovaquone can inhibit the expression of NF-κB (p-P65) and related inflammatory factors by inhibiting the protein expression of p-PDGFRβ, thereby inhibiting colorectal cancer metastasis. Atovaquone may be a promising drug for the treatment of colorectal cancer metastasis.
    Journal
    |
    PDGFRB (Platelet Derived Growth Factor Receptor Beta) • IL6 (Interleukin 6) • CDH1 (Cadherin 1) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCL20 (C-C Motif Chemokine Ligand 20) • IL10 (Interleukin 10) • VIM (Vimentin) • CCL2 (Chemokine (C-C motif) ligand 2) • CDH2 (Cadherin 2) • IL1A (Interleukin 1, alpha) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • IL1B (Interleukin 1, beta) • IL6ST (Interleukin 6 Signal Transducer) • SNAI2 (Snail Family Transcriptional Repressor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • RELA (RELA Proto-Oncogene)
    |
    CDH1 expression • VIM expression • ZEB1 expression
    |
    atovaquone
    6ms
    Spesolimab treatment controls GPP disease characteristics in acute and chronic phases (ISDS 2023)
    Observation of clinical improvements in tandem with reduced IL-36 pathway gene expression suggests that patients can be transitioned from background immunosuppressive therapies to maintenance or rescue spesolimab treatment. Overall, disease suppression may be better maintained via IL-36R blockade compared with current immunosuppressive therapies
    Late-breaking abstract
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • IL17C (Interleukin 17C)
    6ms
    Transcriptomic Analysis of Clonal Hematopoiesis in Solid Tumors Reveals Driver Mutation-Specific Patterns of Immune Dysregulation (ASH 2023)
    This work demonstrates that while general inflammatory changes are evident at the tumor level with CH, there is a critical need to recognize the nuances of CH-associated immune mechanisms in cancer, which appear to vary by cancer type and CH driver. Ongoing efforts will continue to characterize the TIME of the other TCGA cancers through transcriptomic analysis and in situ histological imaging. This study also provides some early clinical evidence for the selection of KMT2C variants in cancer patients, though more work is needed to understand their clonal dynamics and clinical implications.
    IO biomarker • Omic analysis
    |
    DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2C (Lysine Methyltransferase 2C) • CHI3L1 (Chitinase 3-like 1) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • KLRC2 (Killer Cell Lectin Like Receptor C2)
    |
    DNMT3A mutation • ASXL1 mutation • KMT2C mutation • MLL3 mutation
    6ms
    Rutin alleviated lipopolysaccharide-induced damage in goat rumen epithelial cells. (PubMed, Anim Biosci)
    Rutin significantly improved tight junction protein Claudin-1 mRNA expression in LPS-induced GRECs (p<0.01), but could not affect tight junction protein Occludin mRNA expression. Rutin alleviated LPS-induced barrier damage in GRECs by improving oxidation resistance and anti-inflammatory activity, which may be related to TLR/NF-κB signaling pathway inhibition.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • TLR4 (Toll Like Receptor 4) • CLDN1 (Claudin 1) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • IL1B (Interleukin 1, beta) • NFKBIA (NFKB Inhibitor Alpha 2) • TJP1 (Tight Junction Protein 1) • CAT (Catalase) • IRF3 (Interferon Regulatory Factor 3) • OCLN (Occludin) • TLR2 (Toll Like Receptor 2)
    6ms
    Establishment of a prostate cancer prognostic risk model based on the TCGA database and inflammation-related genes (PubMed, Zhonghua Nan Ke Xue)
    The prognostic risk model of inflammation-related genes constructed based on the TCGA database can effectively predict the prognosis of PCa.
    Journal
    |
    CD14 (CD14 Molecule) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1) • IRF7 (Interferon Regulatory Factor 7) • RELA (RELA Proto-Oncogene) • SPHK1 (Sphingosine Kinase 1)
    6ms
    Effects of Electronic Cigarette Aerosol Exposure on Kidney Health in Diabetic/Obese Mice (KIDNEY WEEK 2023)
    Long-term, repeated exposure of diabetic mice to e-cig aerosols containing nicotine induces significant changes in genes involved in CKD progression, cancer, and inflammation. This groundbreaking study reveals the kidney as a target of e-cig use and opens the door for further research concerning the impact of e-cig use on kidney health.
    Preclinical
    |
    EGFR (Epidermal growth factor receptor) • ADAMTS1 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 1) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • ACKR3 (Atypical Chemokine Receptor 3) • CCN1 (Cellular Communication Network Factor 1) • LRRK2 (Leucine Rich Repeat Kinase 2)
    7ms
    MIRACLE: MR Evidence of Cardiac Inflammation Post-Stroke (clinicaltrials.gov)
    P=N/A, N=44, Recruiting, Lawson Health Research Institute | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • MRI
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • FGF19 (Fibroblast growth factor 19) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • TNFRSF9 (TNF Receptor Superfamily Member 9) • CCL20 (C-C Motif Chemokine Ligand 20) • CD5 (CD5 Molecule) • IL10 (Interleukin 10) • CCL19 (C-C Motif Chemokine Ligand 19) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CASP8 (Caspase 8) • CCL2 (Chemokine (C-C motif) ligand 2) • IL18 (Interleukin 18) • TGFB1 (Transforming Growth Factor Beta 1) • CCL8 (C-C Motif Chemokine Ligand 8) • FGF21 (Fibroblast Growth Factor 21) • IL17A (Interleukin 17A) • IL1A (Interleukin 1, alpha) • AXIN1 (Axin 1) • CD40 (CD40 Molecule) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • IL17C (Interleukin 17C) • MMP1 (Matrix metallopeptidase 1) • TNFSF10 (TNF Superfamily Member 10) • TSLP (Thymic Stromal Lymphopoietin) • CDCP1 (CUB Domain Containing Protein 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand) • IL33 (Interleukin 33) • PLAU (Plasminogen Activator) • S100A12 (S100 Calcium Binding Protein A12) • SULT1A1 (Sulfotransferase Family 1A Member 1) • TNFRSF11B (Tumor necrosis factor receptor superfamily member 11B) • TNFSF11 (TNF Superfamily Member 11) • TNFSF14 (TNF Superfamily Member 14)
    7ms
    Activation of Ovarian Cancer G-Protein Coupled Receptor (OGR1) Attenuates Chondrocytes Inflammation via ERK1/2 Signaling Pathways in an in Vitro Model of Osteoarthritis (ACR Convergence 2023)
    Our data suggest that OGR1 is highly expressed in human OA cartilage and regulates inflammatory gene expression via MAPK activation. Our results showed the involvement of OGR1 in the inflammatory pathways and highlights its potential as a therapeutic target for OA treatment. Exploring the mechanisms through which OGR1 influences the development of OA could offer novel perspectives and lead to the development of novel therapies that can modify the course of the disease for individuals with OA.
    Preclinical
    |
    IL6 (Interleukin 6) • CCL3 (C-C Motif Chemokine Ligand 3) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • NOS2 (Nitric Oxide Synthase 2)
    |
    IL6 expression
    7ms
    Bioinformatic Analysis of the CXCR2 Ligands in Cancer Processes. (PubMed, Int J Mol Sci)
    The regulation of the expression of each CXCR2 ligand was different and, thus, each analyzed chemokine may have a different function in cancer processes. Our findings suggest that each type of cancer has a unique pattern of CXCR2 ligand involvement in cancer progression, with each ligand having a unique regulation of expression.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • CXCL3 (C-X-C Motif Chemokine Ligand 3)
    9ms
    An invasive zone in human liver cancer identified by Stereo-seq promotes hepatocyte-tumor cell crosstalk, local immunosuppression and tumor progression. (PubMed, Cell Res)
    Further in vivo experiments using mouse liver tumor models in situ confirmed that the knockdown of genes encoding SAAs in hepatocytes decreased macrophage accumulation around the tumor border and delayed tumor growth. The identification and characterization of a novel invasive zone in human cancer patients not only add an important layer of understanding regarding the mechanisms of tumor invasion and metastasis, but may also pave the way for developing novel therapeutic strategies for advanced liver cancer and other solid tumors.
    Journal • Tumor cell
    |
    SAA1 (Serum Amyloid A1) • CXCL6 (C-X-C Motif Chemokine Ligand 6)
    9ms
    Tumor-Associated Macrophages Affect the Tumor Microenvironment and Radioresistance via the Upregulation of CXCL6/CXCR2 in Hepatocellular Carcinoma. (PubMed, Biomedicines)
    Modulating the TAM/CXCL6/CXCR2 tumor immune signaling axis may be a new treatment strategy for the effective eradication of radiotherapy-resistant hepatocellular carcinoma cells.
    Journal
    |
    IFNG (Interferon, gamma) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
    9ms
    NTRK gene alterations are enriched in gastric cancer with hepatoid differentiation but not in those with DNA mismatch repair protein deficiency (ECP 2023)
    Furthermore, we identified common genes that may be involved in the interaction between the MMR system and NTRK gene alterations in HAS. These results may have important implications for the development of targeted therapies for gastric cancer.
    Mismatch repair
    |
    BIRC3 (Baculoviral IAP repeat containing 3) • NTRK (Neurotrophic receptor tyrosine kinase) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • CACNA1A (Calcium Voltage-Gated Channel Subunit Alpha1 A) • CHRNA7 (Cholinergic Receptor Nicotinic Alpha 7 Subunit) • FGF18 (Fibroblast Growth Factor 18)
    |
    MSI-H/dMMR • NTRK fusion
    10ms
    Identification of PANoptosis-relevant subgroups to evaluate the prognosis and immune landscape of patients with liver hepatocellular carcinoma. (PubMed, Front Cell Dev Biol)
    Two PRDEGs were identified as potential markers. Thus, the understanding of PANoptosis in LIHC was enriched, with some strategies provided for the clinical therapy of LIHC.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL6 (C-X-C Motif Chemokine Ligand 6)
    11ms
    Metastatic colorectal carcinoma-associated fibroblasts display an IGFBP2-dependent immunosuppressive effect on the tumour microenvironment (EACR 2023)
    ConclusionTaken together, these results show that MAFs contribute to an immunosuppressive TME in CRC metastases by modulating the phenotype of immune cells through an IGFBP2-dependent mechanism. Therefore, strategies targeting fibroblast co-expressing IGFBP2 and CD38 might be promising therapeutic target to improve the immunosuppressive state of carcinomatosis patients.
    IO biomarker • Metastases
    |
    IL6 (Interleukin 6) • CD38 (CD38 Molecule) • IL2RA (Interleukin 2 receptor, alpha) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • IGFBP2 (Insulin-like growth factor binding protein 2) • CXCL6 (C-X-C Motif Chemokine Ligand 6)
    |
    CD38 expression • IL2RA expression
    11ms
    circ_0006089 facilitates gastric cancer progression via decoying miR-515-5p and up-regulating CXCL6. (PubMed, Protein Pept Lett)
    Circ_0006089 facilitates the malignant biological behaviors of GC cells via the miR-515- 5p/CXCL6 axis. Circ_0006089 can probably act as one of the important biomarkers and therapeutic targets in GC treatment strategies.
    Journal
    |
    CXCL6 (C-X-C Motif Chemokine Ligand 6)
    11ms
    Identification of key genes for IgA nephropathy based on machine learning algorithm and correlation analysis of immune cells. (PubMed, Transpl Immunol)
    ATF3, FOSB, and CXCL6 genes were identified as potential biomarkers of IgAN. These three genes exhibited good diagnostic efficacy for IgAN. We described the landscape of immune cell infiltration for IgAN. Activated B cells and memory B cells were more highly expressed in the IgAN samples than in the control samples. CXCL6 seems crucial to the pathogenesis of IgAN and may induce IgAN by enriching immune cells. Our study may contribute to developing CXCL6 inhibitors that target B cells for IgAN therapy.
    Journal • Machine learning • Immune cell
    |
    CXCL6 (C-X-C Motif Chemokine Ligand 6) • ATF3 (Activating Transcription Factor 3) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2)
    12ms
    Integrated bioinformatics analysis for conducting a prognostic model and identifying immunotherapeutic targets in gastric cancer. (PubMed, BMC Bioinformatics)
    Our findings provided a risk stratification and prognosis prediction tool for gastric cancer patients and further the research into immunotherapy in gastric cancer.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • CXCL3 (C-X-C Motif Chemokine Ligand 3)
    1year
    Cytokine concentration in peripheral blood of patients with colorectal cancer. (PubMed, Front Immunol)
    Different types of immune cells may share the same chemokine receptors and can co-localise in response to the same chemokines and exert synergistic pro-tumour or anti-tumour functions in the tumour microenvironment. Chemokines and cytokines affect tumour metastasis and prognosis and may be potential targets for treatment.
    Journal
    |
    IFNG (Interferon, gamma) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • IL2 (Interleukin 2) • CCL20 (C-C Motif Chemokine Ligand 20) • CCL19 (C-C Motif Chemokine Ligand 19) • CCL11 (C-C Motif Chemokine Ligand 11) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL8 (C-C Motif Chemokine Ligand 8) • CCL27 (C-C Motif Chemokine Ligand 27) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4)
    1year
    Dissecting the tumor heterogeneity and tumor microenvironment in intrahepatic cholangiocarcinoma using spatial transcriptomics (LCS 2023)
    In biliary malignancies, addition of the immune checkpoint inhibitor to Gemcitabine/Cisplatin has recently become the standard of care in first line treatment, however, the overall survival benefit is moderate in an all-comer population. Our data suggest that an immune suppressive tumor microenvironment associates with suppressive myeloid populations, in addition to high stromal angiogenic activity. Our work thus provides a highly detailed and comprehensive analysis of the iCCA tumor microenvironment and an exploratory analysis of tumor-stromal cell interactions.
    IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • IGF1R (Insulin-like growth factor 1 receptor) • FLT1 (Fms-related tyrosine kinase 1) • IGF1 (Insulin-like growth factor 1) • CXCL6 (C-X-C Motif Chemokine Ligand 6)
    |
    IGF1R expression • VEGFA expression
    |
    cisplatin • gemcitabine
    1year
    CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE. (PubMed, Curr Oncol)
    We preliminary identified CXCL1 and CXCL6 as candidate genes that might have the potential to serve as therapeutically relevant biomarkers in HCC patients. This might pave the way to improve patient selection for TACE in HCC patients beyond expert consensus.
    Journal • Retrospective data
    |
    CD8 (cluster of differentiation 8) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    |
    nCounter® PanCancer Immune Profiling Panel
    1year
    Tumor-Infiltrating Immune Cell Landscapes in the Lymph Node Metastasis of Papillary Thyroid Cancer. (PubMed, Curr Oncol)
    Particularly, patients carrying TG mutations tend to show increased filtration of M2 macrophages and activated NK cells in the TME, whereas patients carrying HRAS mutations tend to show reduced filtration of M0 macrophages and show enhanced filtration of activated dendritic cells in the TME. These findings increase our understanding of the mechanisms of regional lymph node metastasis in PTC and its associated tumor microenvironment, potentially facilitating the development of personalized treatment regimens to combat immunotherapy failure.
    Journal • IO biomarker • Immune cell
    |
    HRAS (Harvey rat sarcoma viral oncogene homolog) • COL1A1 (Collagen Type I Alpha 1 Chain) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • COL11A1 (Collagen Type XI Alpha 1 Chain)
    |
    HRAS mutation
    1year
    Circulating cytokine associations with clinical outcomes in melanoma patients treated with checkpoint inhibitors (AACR 2023)
    Baseline measurement of cytokines IL23, CXCL6, and IL10 can predict metastatic melanoma patients’ response to ipi/nivo combination treatment. Higher neutrophils-to-lymphocytes ratio approximately one month after therapy started associates with worse survival outcome. Our study presented circulating features from a relatively accessible and less costly avenue, peripheral blood, to be predictive of response to combination immune checkpoint blockade.
    Clinical • Clinical data • Checkpoint inhibition
    |
    IL10 (Interleukin 10) • CXCL6 (C-X-C Motif Chemokine Ligand 6)
    |
    IL10-L • IL10 elevation